Alector 과거 수익 실적

과거 기준 확인 0/6

Alector의 수입은 연평균 -0.9%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 19.1%의 비율로 증가했습니다. 매출은 연평균 18.5%의 비율로 증가해 왔습니다.

주요 정보

-0.9%

수익 성장률

6.7%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	18.5%
자기자본 수익률	-133.2%
순이익	-257.5%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 04

AbbVie ends partnership with Alector for Alzheimer’s candidate

Jul 08

Alector: Potential In Neurology And Cancer Treatments

Jun 14

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

May 18

Alector: Expect Phase 3 Data Next Year

Apr 16

These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Feb 27

Alector, Inc: A Newer Biotech Company With Big Potential

Jan 26

수익 및 비용 분석

Alector 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:ALEC 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	62	-158	57	0
30 Jun 24	55	-161	57	-6
31 Mar 24	96	-121	56	0
31 Dec 23	97	-130	57	0
30 Sep 23	96	-141	57	0
30 Jun 23	102	-143	58	87
31 Mar 23	126	-135	60	0
31 Dec 22	134	-133	61	0
30 Sep 22	133	-136	63	0
30 Jun 22	301	36	61	0
31 Mar 22	227	-29	60	0
31 Dec 21	207	-36	55	0
30 Sep 21	198	-33	51	0
30 Jun 21	21	-212	54	0
31 Mar 21	18	-202	56	0
31 Dec 20	21	-190	59	0
30 Sep 20	22	-169	58	0
30 Jun 20	19	-148	51	0
31 Mar 20	23	-127	43	0
31 Dec 19	21	-105	34	0
30 Sep 19	24	-92	27	0
30 Jun 19	28	-76	20	0
31 Mar 19	28	-62	15	0
31 Dec 18	28	-52	12	0
30 Sep 18	22	-45	10	0
30 Jun 18	15	-39	9	0
31 Mar 18	8	-35	8	0
31 Dec 17	4	-32	7	0
31 Dec 16	0	-15	2	0

양질의 수익: ALEC 은(는) 현재 수익성이 없습니다.

이익 마진 증가: ALEC 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: ALEC 은(는) 수익성이 없으며 지난 5년 동안 연간 0.9% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 ALEC 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: ALEC 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: ALEC 현재 수익성이 없기 때문에 마이너스 자본 수익률( -133.19% )을 갖습니다.

Alector 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Recent updates

Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Co-Founder recently sold US$129k worth of stock

Co-Founder recently sold US$129k worth of stock

Board Member recently sold US$228k worth of stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Consensus revenue estimates decrease by 37%, EPS upgraded

Co-Founder notifies of intention to sell stock

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Alector: Good Data, Huge Cash, No Near Term Catalyst

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold US$133k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)

Price target decreased by 12% to US$15.40

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002

Consensus revenue estimates increase by 244%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Price target decreased by 13% to US$14.33

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year 2023

Co-Founder recently sold US$94k worth of stock

Consensus revenue estimates decrease by 24%

Consensus revenue estimates fall by 79%

Key Executive recently sold US$84k worth of stock

Price target decreased by 20% to US$16.94

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021)

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$21.44

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer

Alector, Inc. Announces Resignation of Robert King as Chief Development Officer

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease

Consensus revenue estimates increase by 13%

Price target decreased to US$24.96